{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.0","upperLimit":"51.4","value":"40.7"},{"groupId":"OG001","lowerLimit":"32.7","upperLimit":"52.2","value":"42.4"},{"groupId":"OG002","lowerLimit":"30.0","upperLimit":"48.8","value":"39.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population. Number of participants analyzed=participants with pain score with median PPI \\>= 2 and/or mean analgesic score \\>= 10 points at baseline and at least one valid post-baseline value for specified outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)","title":"Percentage of Participants With Pain Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}